Concurrent Investment Advisors LLC Has $11.38 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Concurrent Investment Advisors LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 139.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,699 shares of the medical research company’s stock after buying an additional 13,232 shares during the period. Concurrent Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $11,380,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in TMO. Tsfg LLC raised its stake in Thermo Fisher Scientific by 20.4% in the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 19 shares in the last quarter. Elyxium Wealth LLC raised its position in shares of Thermo Fisher Scientific by 1.9% in the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after buying an additional 20 shares in the last quarter. Renasant Bank lifted its holdings in shares of Thermo Fisher Scientific by 1.0% during the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock worth $970,000 after acquiring an additional 20 shares during the period. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Finally, Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. boosted its holdings in shares of Thermo Fisher Scientific by 0.7% in the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after purchasing an additional 20 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on TMO. Barclays upped their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 28th. Finally, Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $612.75 on Friday. The business has a 50-day moving average of $570.91 and a 200-day moving average of $515.10. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The company has a market capitalization of $226.56 billion, a price-to-earnings ratio of 32.96, a price-to-earnings-growth ratio of 2.59 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the company earned $4.28 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last quarter. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.